The effect of stereotactic needle biopsy on the size and staging of T1 breast cancer

M. A. Charles, S. B. Edge, D. Driscoll, Thelma C Hurd, P. C. Stomper

Research output: Contribution to journalArticle

Abstract

Stereotactic needle biopsy (SNB) has virtually replaced surgical excision for diagnosis of mammographic-detected breast cancer, SNB by needle core or vacuum-assisted technique may substantially decrease the pathologic size of the cancer determined at subsequent excision, and thus alter tumor stage and recommendations for adjuvant systemic therapy. The objective of this study was to determine the effect of SNB on pathologic tumor size. Methods: The mammographic and pathologic size of 138 mammographicaliy detected invasive cancers with a measurable mammographic mass was reviewed. Group A comprised 61 patients with SNB preceding excision and Group B comprised 77 patients who had excisional biopsy with needle localization (EBNL) as the initial diagnostic procedure. Pathologic size was defined as the size of the invasive component of the cancer from the pathology report. The mammographic size was the size of the central mass determined prospectively without knowledge of pathologic size. The difference between mammographic and pathologic size for each case was determined and compared for Group A and B by the Mann-Whitney test. Results: The median mammographic size was 11 mm for Group A and 10 mm for Group B and the median pathologic size was 10 mm in both groups. The mean difference between mammographic and pathologic size in Group A and B was (-)2.3 mm and (-)1.96 mm, respectively (p NS). There was also no significant difference in the mammographic and pathologic size differential between Groups A and B by histologic type or SNB method (core vs. vacuum assisted). There were no patients in this study where SNB removed the entire lesion. Conclusion: The difference between mammographic size of the central mass of measurable lesions and pathologic size of the invasive component of T1 breast cancer at excision was not changed by the use of SNB compared to excisional biopsy. Except in the circumstance of complete removal of the cancer by SNB, the pathologic size of the excised tumor after SNB appears accurate for staging.

Original languageEnglish (US)
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Needle Biopsy
Breast Neoplasms
Neoplasms
Large-Core Needle Biopsy
Vacuum
Needles
Pathology
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The effect of stereotactic needle biopsy on the size and staging of T1 breast cancer. / Charles, M. A.; Edge, S. B.; Driscoll, D.; Hurd, Thelma C; Stomper, P. C.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 01.01.2001.

Research output: Contribution to journalArticle

Charles, M. A. ; Edge, S. B. ; Driscoll, D. ; Hurd, Thelma C ; Stomper, P. C. / The effect of stereotactic needle biopsy on the size and staging of T1 breast cancer. In: Breast Cancer Research and Treatment. 2001 ; Vol. 69, No. 3.
@article{f940574e606c46d5b73b1384c82b150f,
title = "The effect of stereotactic needle biopsy on the size and staging of T1 breast cancer",
abstract = "Stereotactic needle biopsy (SNB) has virtually replaced surgical excision for diagnosis of mammographic-detected breast cancer, SNB by needle core or vacuum-assisted technique may substantially decrease the pathologic size of the cancer determined at subsequent excision, and thus alter tumor stage and recommendations for adjuvant systemic therapy. The objective of this study was to determine the effect of SNB on pathologic tumor size. Methods: The mammographic and pathologic size of 138 mammographicaliy detected invasive cancers with a measurable mammographic mass was reviewed. Group A comprised 61 patients with SNB preceding excision and Group B comprised 77 patients who had excisional biopsy with needle localization (EBNL) as the initial diagnostic procedure. Pathologic size was defined as the size of the invasive component of the cancer from the pathology report. The mammographic size was the size of the central mass determined prospectively without knowledge of pathologic size. The difference between mammographic and pathologic size for each case was determined and compared for Group A and B by the Mann-Whitney test. Results: The median mammographic size was 11 mm for Group A and 10 mm for Group B and the median pathologic size was 10 mm in both groups. The mean difference between mammographic and pathologic size in Group A and B was (-)2.3 mm and (-)1.96 mm, respectively (p NS). There was also no significant difference in the mammographic and pathologic size differential between Groups A and B by histologic type or SNB method (core vs. vacuum assisted). There were no patients in this study where SNB removed the entire lesion. Conclusion: The difference between mammographic size of the central mass of measurable lesions and pathologic size of the invasive component of T1 breast cancer at excision was not changed by the use of SNB compared to excisional biopsy. Except in the circumstance of complete removal of the cancer by SNB, the pathologic size of the excised tumor after SNB appears accurate for staging.",
author = "Charles, {M. A.} and Edge, {S. B.} and D. Driscoll and Hurd, {Thelma C} and Stomper, {P. C.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "69",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - The effect of stereotactic needle biopsy on the size and staging of T1 breast cancer

AU - Charles, M. A.

AU - Edge, S. B.

AU - Driscoll, D.

AU - Hurd, Thelma C

AU - Stomper, P. C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Stereotactic needle biopsy (SNB) has virtually replaced surgical excision for diagnosis of mammographic-detected breast cancer, SNB by needle core or vacuum-assisted technique may substantially decrease the pathologic size of the cancer determined at subsequent excision, and thus alter tumor stage and recommendations for adjuvant systemic therapy. The objective of this study was to determine the effect of SNB on pathologic tumor size. Methods: The mammographic and pathologic size of 138 mammographicaliy detected invasive cancers with a measurable mammographic mass was reviewed. Group A comprised 61 patients with SNB preceding excision and Group B comprised 77 patients who had excisional biopsy with needle localization (EBNL) as the initial diagnostic procedure. Pathologic size was defined as the size of the invasive component of the cancer from the pathology report. The mammographic size was the size of the central mass determined prospectively without knowledge of pathologic size. The difference between mammographic and pathologic size for each case was determined and compared for Group A and B by the Mann-Whitney test. Results: The median mammographic size was 11 mm for Group A and 10 mm for Group B and the median pathologic size was 10 mm in both groups. The mean difference between mammographic and pathologic size in Group A and B was (-)2.3 mm and (-)1.96 mm, respectively (p NS). There was also no significant difference in the mammographic and pathologic size differential between Groups A and B by histologic type or SNB method (core vs. vacuum assisted). There were no patients in this study where SNB removed the entire lesion. Conclusion: The difference between mammographic size of the central mass of measurable lesions and pathologic size of the invasive component of T1 breast cancer at excision was not changed by the use of SNB compared to excisional biopsy. Except in the circumstance of complete removal of the cancer by SNB, the pathologic size of the excised tumor after SNB appears accurate for staging.

AB - Stereotactic needle biopsy (SNB) has virtually replaced surgical excision for diagnosis of mammographic-detected breast cancer, SNB by needle core or vacuum-assisted technique may substantially decrease the pathologic size of the cancer determined at subsequent excision, and thus alter tumor stage and recommendations for adjuvant systemic therapy. The objective of this study was to determine the effect of SNB on pathologic tumor size. Methods: The mammographic and pathologic size of 138 mammographicaliy detected invasive cancers with a measurable mammographic mass was reviewed. Group A comprised 61 patients with SNB preceding excision and Group B comprised 77 patients who had excisional biopsy with needle localization (EBNL) as the initial diagnostic procedure. Pathologic size was defined as the size of the invasive component of the cancer from the pathology report. The mammographic size was the size of the central mass determined prospectively without knowledge of pathologic size. The difference between mammographic and pathologic size for each case was determined and compared for Group A and B by the Mann-Whitney test. Results: The median mammographic size was 11 mm for Group A and 10 mm for Group B and the median pathologic size was 10 mm in both groups. The mean difference between mammographic and pathologic size in Group A and B was (-)2.3 mm and (-)1.96 mm, respectively (p NS). There was also no significant difference in the mammographic and pathologic size differential between Groups A and B by histologic type or SNB method (core vs. vacuum assisted). There were no patients in this study where SNB removed the entire lesion. Conclusion: The difference between mammographic size of the central mass of measurable lesions and pathologic size of the invasive component of T1 breast cancer at excision was not changed by the use of SNB compared to excisional biopsy. Except in the circumstance of complete removal of the cancer by SNB, the pathologic size of the excised tumor after SNB appears accurate for staging.

UR - http://www.scopus.com/inward/record.url?scp=33749093804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749093804&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749093804

VL - 69

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -